NeuroNEXT will provide a robust, standardized, and accessible infrastructure to facilitate rapid development and implementation of protocols in neurological disorders affecting adult and/or pediatric populations. The network includes multiple Clinical Sites, one Clinical Coordinating Center (CCC) and one Data Coordinating Center (DCC).
Network website: www.neuronext.org
You DO NOT need to be part of the NeuroNEXT infrastructure to apply to conduct a study within the network. Applications from academic investigators, advocacy groups/foundations, small businesses and the pharmaceutical industry are welcomed.Expand each group by clicking ( ). Expand All | Close All
NeuroNEXT is intended to facilitate the testing of novel therapeutics (drugs, biologics, devices) for neurological disorders. These novel therapeutics may come from academic investigators or directly from the biotechnology or pharmaceutical sector. NeuroNEXT aims to support scientifically sound phase 2 clinical trials that provide data for clear go/no-go decisions. Biomarker validation studies are also considered either independently or as part of a therapeutic trial.
Working with NeuroNEXT is a cooperative venture between NINDS, the NeuroNEXT network and the applicant. NINDS will provide guidance to potential applicants with input from the Office of Clinical Research (OCR), the applicable NINDS Extramural office/cluster and the NeuroNEXT Executive Committee (NEC). Potential applicants should contact NINDS OCR in order to discuss the feasibility of conducting the proposed trial through the NeuroNEXT infrastructure.
There are three mechanisms available for potential applicants:
Information for potential industry collaborators:
Information for potential advocacy collaborators:
Potential applicants whose clinical research cannot be supported through NeuroNEXT are encouraged to consider an alternate funding mechanism:
NeuroNEXT Clinical Trials (U01) - Standard dates apply for scientific merit review of applications coming under the U01 grant mechanism: for detailed information, please refer to Section V. Application Review Information in PAR-11-343.
NeuroNEXT Infrastructure Resource Access (X01) - Expedited dates apply for scientific merit review of applications coming under the X01 grant mechanism: for detailed information, please refer to Section V. Application Review Information in PAR-11-344.
NeuroNEXT Small Business Innovation in Clinical Trials (U44) - Standard dates apply for scientific merit review of applications coming under the U44 grant mechanism: for detailed information,
please refer to Section V. Application Review Information in PAR-11-345.
Questions? Please email NEXT@ninds.nih.gov
Last updated March 20, 2013